// App-Quantinova.ai

308 : Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies

Researchers

Presenter

  • Joseph Merola

Principal Investigators

  • Kristina Callis-Duffin

  • Byron Padilla

  • Cuiyong Yue

  • Huzefa Photowala

  • Blair Kaplan

  • Iain B McInnes

Medical Centers

  • University of Utah, Salt Lake City, UT

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03675308

  • NCT03671148

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved